Oncology Nursing Society (ONS)

The Oncology Nursing Society (ONS) is a professional association that represents 100,000 nurses and is the professional home to more than 35,000 members. ONS is committed to promoting excellence in oncology nursing and the transformation of cancer care. Since 1975, ONS has provided a professional community for oncology nurses, developed evidence-based education programs and treatment information, and advocated for patient care, all in an effort to improve the quality of life and outcomes for patients with cancer and their families.
Utilizing Nursing Handoff Communication to Manage Immune-Related Adverse Events in an Outpatient Immunotherapy Clinic
ONS 2017 – Immunotherapy
Immunotherapy represents a groundbreaking advance in the care of cancer patients. It modulates the body’s immune system to promote tumor destruction, and is now considered the fourth pillar of cancer treatment. Immunotherapeutic agents are associated with higher rates of immune-related adverse events that require immediate identification and intervention to prevent treatment cessation or fatal consequences. Read More ›
Leveraging Technology to Optimize the Care of Patients Treated with Immunotherapy
ONS 2017 – Immunotherapy
Immunotherapy represents a revolutionary advance in the care of cancer patients, and is now considered the fourth pillar of cancer treatment. Immunomodulating agents promote tumor destruction and enhance patient survival. They also result in a higher incidence of immune-related adverse events that require prompt recognition for effective management. Read More ›
Combination Therapy in Patients with Metastatic Melanoma, NSCLC, and RCC
ONS 2017 – Immunotherapy
Nivolumab is an immune checkpoint inhibitor proved to extend survival in patients with metastatic melanoma, non–small-cell lung cancer (NSCLC), and renal-cell carcinoma (RCC). When patients receive nivolumab combined with ipilimumab, they experience higher tumor response rates and increased progression-free survival. Patients receiving combined immunotherapeutic agents experience higher rates of immune-related adverse events compared with patients receiving monotherapy. Read More ›
Overcoming HER2/ER Crosstalk: Neratinib Alone or in Combination with Fulvestrant in ER-Positive, HER2-Mutant Metastatic Breast Cancer in the Phase 2 SUMMIT Trial
ONS 2017 – Immunotherapy
The open-label, international, multicenter, multinational, phase 2 SUMMIT trial explored the efficacy and safety of neratinib monotherapy in patients with HER2-mutant metastatic breast cancer (MBC), and neratinib in combination with fulvestrant in patients with estrogen receptor (ER)-positive and HER2-positive MBC. Read More ›
Mechanism of Action of Neratinib: An Irreversible Pan-HER Inhibitor in Late-Stage Clinical Development
ONS 2017 – Immunotherapy
Trastuzumab is a monoclonal antibody used for the treatment of HER2-positive breast cancer. Despite the efficacy of trastuzumab in the adjuvant setting, 1 in 4 patients experience disease recurrence. Neratinib is a potent, irreversible, pan-HER tyrosine kinase inhibitor that can combat mechanisms of disease escape and recurrence experienced with other HER2-targeted therapies. Read More ›
The ONS 40th Annual Congress
ONS 2015
The 2015 Annual Congress of the Oncology Nursing Society (ONS) marks the 40th anniversary of the organization. Presentations and events included the tried and true and the new. Read More ›
Boosting Uptake of the HPV Vaccine
ONS 2015
The United States lags behind other developed countries in uptake of the human papillomavirus (HPV) vaccine, and nurses and other healthcare providers can improve the situation. Read More ›

Page 3 of 3


© Amplity, Inc. All Rights Reserved. Privacy Policy